Signaling Pathway News and Research

RSS

Afinitor Phase III study on angiomyolipomas associated with TSC meets primary endpoint

A Phase III study of Afinitor (everolimus) tablets in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis complex (TSC) met its primary endpoint of best overall angiomyolipoma response rate, which includes reduction in kidney tumor size and absence of new tumors.

26 Sep 2011

Wnt signaling pathway plays an important role in early-onset dementia

No cure exists for frontotemporal dementia, which strikes between the ages of 40 and 64 and accounts for at least one in four cases of early-onset dementia. Caused by the death of cells in the front and sides of the brain, the disease can lead to dramatic changes in a patient's personality and behavior, including the loss of the ability to communicate.

22 Sep 2011

Study reveals possible new treatment targets for diffuse intrinsic pontine gliomas

Study led by St. Jude Children's Research Hospital scientists points to possible new treatment targets for diffuse intrinsic pontine gliomas; may tip the scales in the current debate about tumor biopsies.

21 Sep 2011

Researchers identify promising new therapies for ependymoma

Researchers have identified promising new therapies for ependymoma, a rare tumor with few treatment options. St. Jude Children's Research Hospital investigators led the effort, which used a new, faster drug development system that combines the latest drug screening technology with the first accurate animal model of the tumor.

16 Sep 2011

Curcumin suppresses cell signaling pathway that drives growth of head and neck cancer

Curcumin, the main component in the spice turmeric, suppresses a cell signaling pathway that drives the growth of head and neck cancer, according to a pilot study using human saliva by researchers at UCLA's Jonsson Comprehensive Cancer Center.

14 Sep 2011

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon Inc. today announced enrollment of the first patient in a Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer. PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway.

12 Sep 2011

Scientists discover backup circuits in cetuximab-resistant cancer cells

Scientists at Dana-Farber Cancer Institute and colleagues overseas have discovered a pair of backup circuits in cancer cells that enable the cells to dodge the effect of a widely used cancer drug.

8 Sep 2011

New medicines to target LPA receptors may prevent serious developmental brain diseases

Examining brain damage that occurs when fetuses in the womb are deprived of oxygen, researchers at The Scripps Research Institute have discovered that damage does not occur randomly but is linked to the specific action of a naturally occurring fatty molecule called LPA, acting through a receptor that transfers information into young brain cells.

2 Sep 2011

UVA researchers develop 3-D model to visualize early growth of human breast tissue

University of Virginia researchers have developed a revolutionary three-dimensional model that allows them to visualize how breast tissue grows in its earliest stages, giving them the closest look ever at the very beginnings of breast cancer.

2 Sep 2011

Student researchers throughout Australia compete for annual award

Student researchers from throughout Australia will compete for state and national titles in the country’s leading competition for life science, biotechnology and bio-engineering students: the 2011 AusBiotech-GSK Student Excellence Awards. Applications are now open for the 2011 awards.

29 Aug 2011

Repeated cocaine use can increase individual's risk of mood disorders

It is well established that a mood disorder can increase an individual's risk for substance abuse, but there is also evidence that the converse is true; substance abuse can increase a person's vulnerability to stress-related illnesses.

25 Aug 2011

IGF1 plays key role in T-cell acute lymphoblastic leukemia

There are numerous specialized growth factors that are responsible for cells of different tissues of our body to divide and differentiate when needed. These hormone-like factors bind to matching receptors on the surface of their target cells and thus give order for the cell to divide. However, a single genetic alteration can be sufficient for the whole system to get out of control.

24 Aug 2011

Scientists identify molecular pathway that plays a key role in stress-related DNA damage

Working closely with a team of researchers from Duke University, scientists from the Florida campus of The Scripps Research Institute have helped identify a molecular pathway that plays a key role in stress-related damage to the genome, the entirety of an organism's hereditary information.

23 Aug 2011

Semaphorin-PlexinD1 signaling pathway shows promise as therapeutic target for cancer treatment

In a new study published in the August 16th issue of Developmental Cell, researchers at NYU Langone Medical Center identified a molecular mechanism that guarantees that new blood vessels form in the right place and with the proper abundance.

17 Aug 2011

Pfizer, QIAGEN partner to develop diagnostic-therapeutic combination for NSCLC

QIAGEN today announced it has entered into a partnership with Pfizer Inc. for the development of a companion molecular diagnostic test for use with an investigational Pfizer compound in global clinical development for treatment of non-small cell lung cancer.

From QIAGEN Manchester Limited 16 Aug 2011

Scientists identify new therapeutic target for ADHD, other neuropsychiatric disorders

A biochemical pathway long associated with diarrhea and intestinal function may provide a new therapeutic target for treating ADHD other neuropsychiatric disorders, according to a team of scientists from China and the United States reporting Aug. 11 in Science.

12 Aug 2011

Scientist determines how nyctalopin gene makes night vision possible

A scientist from the Florida campus of The Scripps Research Institute has determined how a particular gene makes night vision possible. The study, which was published in the August 10, 2011 edition of The Journal of Neuroscience, focuses on a gene called nyctalopin. Mutations in the gene result in inherited "night blindness," a loss of vision in low-light environments.

10 Aug 2011

Novel DNA sensing pathway linked to increased susceptibility to malaria

Scientists at the University of Massachusetts Medical School have uncovered a novel DNA-sensing pathway important to the triggering of an innate immune response for malaria. Activation of this pathway appears to stimulate production of an overabundance of type-1 interferon by the immune system that may contribute to inflammation and fever in malaria patients and could play a part in susceptibility for the most common and lethal form of malaria known as plasmodium falciparum.

5 Aug 2011

PCF funds 10 new Challenge Awards for prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 10 new Challenge Awards for accelerating scientific discovery and new treatments for prostate cancer patients.